Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 1841Neoplasms 1230Colorectal Neoplasms 1046Carcinoma, Non-Small-Cell Lung 996Stomach Neoplasms 787Carcinoma, Hepatocellular 780Lung Neoplasms 756Prostatic Neoplasms 682Pancreatic Neoplasms 567Rectal Neoplasms 444Colonic Neoplasms 401Neoplasm Metastasis 400Ovarian Neoplasms 399Uterine Cervical Neoplasms 395Recurrence 380Leukemia, Myeloid, Acute 367Esophageal Neoplasms 352Multiple Myeloma 340Lymphoma 330Head and Neck Neoplasms 326Melanoma 306Precursor Cell Lymphoblastic Leukemia-Lymphoma 288Brain Neoplasms 263Urinary Bladder Neoplasms 249Nasopharyngeal Carcinoma 221Liver Neoplasms 221Leukemia 217Lymphoma, Large B-Cell, Diffuse 213Polycystic Ovary Syndrome 206Squamous Cell Carcinoma of Head and Neck 200

Interventions

repaglinide 1Bupropion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Prostate Cancer Patients × Clear all
NCT04664725 2020-12-11

Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown
18 enrolled
Genitourinary

Prostate Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡